Skip to main content

Advertisement

SpringerLink
Log in

Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma

  • Original Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The aim of our study was to assess the intrapatient variability of 2-deoxy-2-(18F)-fluoro-D-glucose (18F-FDG) uptake in the liver and in the mediastinum among patients with Hodgkin’s lymphoma (HL) treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy (CHT).

Methods

The study included 68 patients (30 men, 38 women; mean age 32 ± 11 years) with biopsy-proven HL. According to Ann Arbor criteria, 6 were stage I, 34 were stage II, 12 were stage 3 and 16 were stage 4. All of them underwent a baseline (PET0) and an interim (PET2) 18F-FDG whole-body positron emission tomography (PET)/CT. All patients were treated after PET0 with two ABVD cycles for 2 months that ended 15 ± 5 days prior to the PET2 examination. All patients were further evaluated 15 ± 6 days after four additional ABVD cycles (PET6). None of the patients presented a serum glucose level higher than 107 mg/dl. The mean and maximum standardized uptake values (SUV) of the liver and mediastinum were calculated using the same standard protocol for PET0, PET2 and PET6, respectively. Data were examined by means of the Wilcoxon matched pairs test and linear regression analysis.

Results

The main results of our study were an increased liver SUVmean in PET2 (1.76 ± 0.35) as compared with that of PET0 (1.57 ± 0.31; p < 0.0001) and PET6 (1.69 ± 0.28; p = 0.0407). The same results were obtained when considering liver SUVmax in PET2 (3.13 ± 0.67) as compared with that of PET0 (2.82 ± 0.64; p < 0.0001) and PET6 (2.96 ± 0.52; p = 0.0105). No significant differences were obtained when comparing mediastinum SUVmean and SUVmax in PET0, PET2 and PET6 (p > 0.05). Another finding is a relationship in PET0 between liver SUVmean and SUVmax with the stage, which was lower in those patients with advanced disease (r 2 = 0.1456 and p = 0.0013 for SUVmean and r 2 = 0.1277 and p = 0.0028 for SUVmax).

Conclusion

The results of our study suggest that liver 18F-FDG uptake is variable in patients with HL during the CHT treatment and the disease course and should be considered carefully when used to define the response to therapy in the interim PET in HL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16:1160–8.

    Article  CAS  PubMed  Google Scholar 

  2. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006;107:52–9.

    Article  CAS  PubMed  Google Scholar 

  3. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin’s disease patients. Ann Oncol 2006;17:1296–300.

    Article  CAS  PubMed  Google Scholar 

  4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.

    Article  PubMed  Google Scholar 

  5. Evens AM, Hutchings M, Diehl V. Treatment of Hodgkin lymphoma: the past, present, and future. Nat Clin Pract Oncol 2008;5:543–56.

    Article  CAS  PubMed  Google Scholar 

  6. Hancock SL, Hoppe RT. Long-term complications of treatment and causes of mortality after Hodgkin’s disease. Semin Radiat Oncol 1996;6:225–42.

    Article  PubMed  Google Scholar 

  7. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–6.

    CAS  PubMed  Google Scholar 

  8. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009;50:1761–4.

    Article  PubMed  Google Scholar 

  9. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med 2013;54:683–90.

    Article  CAS  PubMed  Google Scholar 

  10. Ceriani L, Suriano S, Ruberto T, Zucca E, Giovanella L. 18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. Clin Nucl Med 2012;37:949–52.

    Article  PubMed  Google Scholar 

  11. Boktor RR, Walker G, Stacey R, Gledhill S, Pitman AG. Reference range for intrapatient variability in blood-pool and liver SUV for 18F-FDG PET. J Nucl Med 2013;54:677–82.

    Article  CAS  PubMed  Google Scholar 

  12. Groheux D, Delord M, Rubello D, Colletti PM, Nguyen ML, Hindie E. Variation of liver SUV on (18)FDG-PET/CT studies in women with breast cancer. Clin Nucl Med 2013;38:422–5.

    Article  PubMed  Google Scholar 

  13. Gallamini A, Patti C, Viviani S, Rossi A, Fiore F, Di Raimondo F, et al. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Br J Haematol 2011;152:551–60.

    Article  PubMed  Google Scholar 

  14. Boellaard R, O’Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010;37:181–200.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Schillaci O, Travascio L, Bolacchi F, Calabria F, Bruni C, Cicciò C, et al. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients. Radiol Med 2009;114:890–906.

    Article  CAS  PubMed  Google Scholar 

  16. Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. Biol Rev Camb Philos Soc 2007;82:591–605.

    Article  PubMed  Google Scholar 

  17. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum; 1988.

    Google Scholar 

  18. Robinson PJ. The effects of cancer chemotherapy on liver imaging. Eur Radiol 2009;19:1752–62.

    Article  PubMed  Google Scholar 

  19. Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin’s disease trial. N Engl J Med 2002;346:1417–8.

    Article  PubMed  Google Scholar 

  20. Borchmann P, Engert A. The past: what we have learned in the last decade. Hematology Am Soc Hematol Educ Program 2010;2010:101–7.

    Article  PubMed  Google Scholar 

  21. Rueda Domínguez A, Márquez A, Gumá J, Llanos M, Herrero J, de Las Nieves MA, et al. Treatment of stage I and II Hodgkin’s lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798–804.

    Article  PubMed  Google Scholar 

  22. Enger A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 2010;363:640–52.

    Article  Google Scholar 

  23. Boleti E, Mead GM. ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol 2007;18:376–80.

    Article  CAS  PubMed  Google Scholar 

  24. Owadally WS, Sydes MR, Radford JA, Hancock BW, Cullen MH, Stenning SP, et al. Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Ann Oncol 2010;21:568–73.

    Article  CAS  PubMed  Google Scholar 

  25. Chiaravalloti A, Pagani M, Di Pietro B, Danieli R, Tavolozza M, Travascio L, et al. Is cerebral glucose metabolism affected by chemotherapy in patients with Hodgkin’s lymphoma? Nucl Med Commun 2013;34:57–63.

    Article  CAS  PubMed  Google Scholar 

  26. Jaskowiak CJ, Bianco JA, Perlman SB, Fine JP. Influence of reconstruction iterations on 18F-FDG PET/CT standardized uptake values. J Nucl Med 2005;46:424–8.

    PubMed  Google Scholar 

  27. Chin BB, Green ED, Turkington TG, Hawk TC, Coleman RE. Increasing uptake time in FDG-PET: standardized uptake values in normal tissues at 1 versus 3 h. Mol Imaging Biol 2009;11:118–22.

    Article  PubMed  Google Scholar 

  28. Batallés SM, Villavicencio RL, Quaranta A, Burgos L, Trezzo S, Staffieri R, et al. Variations of the hepatic SUV in relation to the body mass index in whole body PET-CT studies. Rev Esp Med Nucl Imagen Mol 2013;32:26–32.

    PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Biomedicine and Prevention, University Tor Vergata, Viale Oxford 81, 00133, Rome, Italy

    Agostino Chiaravalloti, Roberta Danieli, Paolo Abbatiello, Barbara Di Pietro, Laura Travascio, Maria Cantonetti, Manlio Guazzaroni, Antonio Orlacchio, Giovanni Simonetti & Orazio Schillaci

  2. IRCCS Neuromed, Pozzilli, Italy

    Orazio Schillaci

Authors
  1. Agostino Chiaravalloti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Roberta Danieli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paolo Abbatiello
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Barbara Di Pietro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Travascio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Cantonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Manlio Guazzaroni
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Antonio Orlacchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Giovanni Simonetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Orazio Schillaci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Agostino Chiaravalloti.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chiaravalloti, A., Danieli, R., Abbatiello, P. et al. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 41, 1123–1132 (2014). https://doi.org/10.1007/s00259-014-2703-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-014-2703-0

Keywords

Search

Navigation